A cell therapy called EB103 for adults with B-cell lymphoma that came back
Original title: T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, so a lot is still unknown.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a cell therapy for adults whose B-cell lymphoma came back or never went away.
Who this trial is for. It is for adults with B-cell non-Hodgkin's lymphoma that came back or did not respond to treatment. It includes people with lymphoma in the brain or spinal cord, people with HIV-related lymphoma, people with high-grade B-cell lymphomas, and people with large B-cell lymphoma who cannot have a transplant using their own stem cells. The study is testing a cell therapy called EB103.
Where it stands. The study is looking at how safe EB103 is and how well it works. That answer is not in yet. This trial has not reported results.
What this means, and what it doesn't
What it could mean: This is one place where a new cell therapy is being tested. It includes people who often have few choices left, such as those with lymphoma in the brain or spinal cord. Someone who thinks they may fit can ask their care team about it. The care team can say if it makes sense to look into.
What it doesn't mean: This does not mean EB103 works. A trial is a test, not a proven treatment. Joining a study is not a promise that it will help you. It is not a cure, and no one can say yet what it will do. The trial team decides who can take part.
Source: ClinicalTrials.gov, October 1, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.